Wockhardt announced that its novel intravenous antibiotic Foviscu (WCK 4282) has successfully met the primary endpoint in a Phase 3 clinical trial in patients with complicated urinary tract infections ...

Extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E) have become a critical global public health challenge due to their high resistance to β-lactam antibiotics and association with severe ...

In a recent study published in the Microbiology Spectrum Journal, researchers suggest that Escherichia coli ST2797 could potentially be a new type of extended-spectrum beta-lactamase (ESBL) ...

Objective: Neonatal colonization of the gut with multiresistant (ESBL= Extended spectrum betalactamase) gram-negative bacteria has become more common in recent years. The aim of this study was to ...

Please provide your email address to receive an email when new articles are posted on . Carbapenems were prescribed as targeted therapy in 58.3% of all infections. Highlighting patient populations ...

WALTHAM, Mass.--(BUSINESS WIRE)--Entasis Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced initiation ...

Individual risk assessment with automated EHR alerts are an effective and safe strategy to limit use of extended-spectrum antibiotics in patients hospitalized with UTI. An antibiotic stewardship ...

Background. Extended-spectrum ß-lactamase-producing Escherichia coli (ESBL-EC) is an important cause of invasive infections. Alternatives to carbapenems—considered the drugs of choice—are needed ...

Background. The determinants of the spread of extended-spectrum β-lactamase–producing Escherichia coli (ESBLEC) in the community remain unclear. To evaluate its dissemination in the environment, we ...

Purpose: Recently, we have noticed an increased incidence of infections caused by antibiotic-resistant pathogens including ESBL-producing microorganisms in our NICU patients. The purpose of this study ...